Marpai, Inc. (MRAI): R&D Expense

Annual figures by period end, from SEC filings.

$7.0K
Year ended 2025-12-31
-87.6%
3-year compound annual growth
-66.9%
5-year compound annual growth
$3.71M2020-12-31: $1.77M2021-12-31: $1.73M2022-12-31: $3.71M2023-12-31: $1.31M2024-12-31: $29.0K2025-12-31: $7.0K$7.0K
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$7.0K-75.9%2026-03-25, From 2025-01-01
2024-12-31$29.0K-97.8%2026-03-25, From 2024-01-01
2023-12-31$1.31M-64.6%2025-03-27, From 2023-01-01
2022-12-31$3.71M+113.8%2024-03-26, From 2022-01-01
2021-12-31$1.73M-1.8%2023-07-27, From 2021-01-01
2020-12-31$1.77Mn/a2022-03-30, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Misc Health & Allied Services, NEC), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Marpai, Inc. (MRAI)2025-12-31$7.0K-75.9%
Cryo Cell International Inc (CCEL)2025-11-30$376.3K-69.7%
Viemed Healthcare, Inc. (VMD)2025-12-31$3.02M-1.7%
BioRestorative Therapies, Inc. (BRTX)2025-12-31$10.09M+50.5%
Progyny, Inc. (PGNY)2025-12-31$9.50Mn/a

Compare MRAI, CCEL, VMD, BRTX side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗